SPC for ezetimibe/simvastatin considered invalid in preliminary relief proceedings
Targeted treatments – Part 3: the power of orphan drug protection
Targeted treatments – Part 1: Targeted treatments: patents for particular populations
Return to work: key issues for life sciences
作者 Helen Farr 以及 Adrian Toutoungi
Private equity investment in life sciences sector
Exploring some of the potential benefits and challenges for life sciences companies considering PE investment.
作者
4 / 6 观点